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The variousorganisms responsible forvisceral, cutaneous, and mucocutaneous
leishmaniasis have evolved characteristically the strategy of evading the host
immune system by invading reticuloendothelial cells. Their ability to find safety
in phagocytic cells prompts many intriguing questions. Foremost among these
are how they are taken up by these cells and how they avoid being killed. Recent
work on the uptake question points to the complement receptor for C3bi, CR3,
as a major mechanism for the uptake of leishmania promastigotes (1, 2). A
monoclonal antibody (anti-Mac-1) that is specific to CR3 can block uptake by
>50%. However, this inhibition cannot be increased by the addition of more
antibody. The inability of this monoclonal antibody to further inhibit binding
suggests that an additional mechanism for uptake may be operating.
A novel receptor has recently been noted in macrophages that binds selectively
to proteins containing covalently attached advanced glycosylation endproducts
(AGE)' (3, 4). These AGEsarisefrom the time-dependent nonenzymatic reaction
of glucose with proteins (5). The precise chemical identity of only one of this
family of AGEs has been established (6). In this case, two glucose molecules and
two protein amino groups condense to form the fluorescent yellow pigment 2-
furoyl-4(5)-(2-1-H-furanyl)-imidazole (FFI). The receptor on macrophages that
binds the AGE moieties is distinct from other scavenger receptors (7) and may
play a role in the removalofsenescentproteins and cells. Reasoning that parasites
ofthe macrophage may wish to gain entry via such a scavenger pathway, we have
evaluated the role of the AGE-protein receptor in the binding and uptake of
leishmania. In the present communication, we report that binding of promasti-
gotes of Leishmania major is inhibited by 50% by the addition ofthe ligand AGE-
albumin (AGE-BSA). This inhibition is additive with inhibition of the macro-
phage CR3 by anti-Mac-1, and in combination, anti-Mac-1 and AGE-BSA specif-
ically inhibit leishmania uptake by 90%.
Address correspondence to D. M. Mosser.
' Abbreviations used in thispaper:
￿
AGE, advanced glycosylated endproducts; FFI, 2-furoyl-4(5)-(2-
I-Hfuranyl)-imidazole.
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Materials and Methods
Macrophages. Resident macrophages were obtained from the peritoneal cavity of
BALB/c mice (Rockefeller University LARC) as described previously (8). The adherent
cells were incubated in DMEM supplemented with 10% heat inactivated FCS for 1 h,
washed, and incubated overnight at 37 °C. Before the addition of parasites, cells were
washed two times with phagocytosis buffer that contained 0.25% BSA and equal parts of
DMEM and TC-199 buffered with 25 mM Hepes buffer, pH 7.2.
Parasites.
￿
The National Institutes of Health S-strain of Leishmania major, originally
isolated from a patient with a cutaneous ulcer in West Africa, was kindly provided by Dr.
David Wyler, Tufts University Medical Center, Boston, MA (9). Promastigotes were
grown in Schneider's Complete Drosophila Medium as described previously (10).
Parasite Binding Assay.
￿
For the binding assay, promastigotes were radiolabeled with
[sH]uracil as previously described (10). Briefly, cultivated promastigotes, at a cell density
of -4 x 107 parasites/ml, were washed and resuspended in 5 ml Schneider's Complete
Medium (10) containing 30 uCi[sH]uracil (sp act 26.8 Ci/mmol; New England Nuclear,
Boston, MA) for 4 h. Parasites were washed three times and resuspended to a concentra-
tion of 2 x 107 parasites/ml in phagocytosis buffer. 50 IA1 of labeled parasites were added
to monolayers of macrophages that had been seeded on 13-mm coverslips in multiwell
plates, in the presence of the designated inhibitors, and the overlay was brought to 0.4
ml with phagocytosis buffer. Parallel binding assays were also quantitated at the light level
to allow calculation of binding on a per-cell basis, as described (10).
Inhibitors. Anti-Mac-1, a monoclonal antibody to the CR3, initially described by
Springer et al. (11), was precipitated from culture supernatants by ammonium sulfate and
purified on DEAF-cellulose. It was used at a final concentration of 7 kg/ml as described
previously (1). AGE-BSA was made by incubating BSA in 50 mM glucose in 0.1 M PBS,
pH 7.4 at 37 ° C for 3-4 wk in the presence of protease inhibitors and antibiotics, as
described (3). FFI-BSA was prepared as described previously (3).
Cytochrome C Reduction Assay.
￿
Macrophage superoxide production was quantitated by
measuring the reduction of extracellular cytochrome C as described by Johnston (12).
Monolayers were incubated in HBSS containing 4 mg/ml glucose and 80 14M cytochrome
C (Sigma Chemical Co., St. Louis, MO). Parasites in HBSS were added for 30 min at
37°C, at which time the cytochrome-containing overlay was removed and centrifuged to
remove free parasites. The absorbance at 550 nm was determined against an appropriate
cell-free blank. Cell-free wells containing parasites alone or inhibitors alone were run in
parallel as controls. Monolayers were also exposed to parasites in the presence of 150 U
superoxide dismutase (Sigma Chemical Co.).
Results and Discussion
Incubation of L. major promastigotes with macrophages in serum-free medium
leads to parasite binding and uptake. After 45 min, at a parasite inoculum of 2 .5
x I0' parasites/ml, -55% ofthe 105 macrophages present on 13-mm-diam round
coverslips have bound at least one parasite, with a total of 1 .5 x 105 parasites
being bound on average per coverslip. ^-85% of the attached parasites are
internalized during this period. Preincubation of macrophage cultures for 20
min with AGE-BSA decreases, in a concentration-dependent manner, the total
number of parasites bound (Fig. 1) and the number of macrophages binding at
least one parasite. Addition of underivatized BSA (I mg/ml) to cultures did not
interfere with binding or uptake. With this particular preparation of AGE-BSA,
maximal inhibition occurred at 125 Pg/ml, decreasing the total number of
parasites taken up per monolayer by 60.4 ± 5.2% . The average number of
parasites bound decreases in the presence of AGE-BSA from 1 .65 parasites per
macrophage to 0 .79 (Table 1), while the percentage of cells containing at least
one parasite decreases from 55 to 36%. Other AGE-BSA preparations inhibited142 MACROPHAGE RECEPTOR FOR LEISHMANIA PROMASTIGOTES
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FIGURE 1 .
￿
The inhibition of promastigote bindingto macrophages by AGE-BSA. Increasing
concentrations of AGE-BSA were added to macrophages for 20 min before, and during the
addition of target particles. The percent inhibition is calculated by dividing the number of
particles bound per macrophage in the presence of inhibitors by the number bound without
inhibitors and subtracting that value from 1. Target particles included L. major promastigotes
(circles), zymosan (x), or C3bi-RBCs (squares). Zymosan and C3bi-RBC bindingwere scored
microscopically, while L. major binding was quantitated with the parasite radiobinding assay
as described in Materialsand Methods.
TABLE I
Effects of Glycosylated BSA Derivatives on Binding ofL. major Promastigotes to Macrophages
and theirStimulation of the Respiratory Burst
* AGE-BSA, FFI-BSA, and native BSA were each used at a final concentration of 125 fag/ml. Anti-
Mac-I was used at a final concentration of 7 ug/ml.
$ The number of particles/cell determined by the radiobinding assay for parasites and by light
microscopy for C3bi-RBCsand zymosan. The variance in the radiobinding assay is ±15% .
¢The respiratory burst was quantitated by measuring the reduction of cytochrome C as described
in Materialsand Methods. It is expressed in nanomoles of reduced 02 per milligram of protein.
74% of the macrophages formed rosettes with threeor more red bloodcells.
' 87% of the cells had bound three or more zymosan particles.
Stimulus Treatment n
Particles/
macro-
phaget
Reduced oxygen
(nmol/mg)I
L. major None 5 1.65 139.2 ± 6.0
AGE-BSA 2 0.79 73.8 ± 14.4
Anti-Mac-I 3 0.70 75.0 ± 9.0
AGE-BSA + anti-Mac-1 3 0.19 24.1 ± 6.2
FFI-BSA 2 1 .77 144.0 ± 18.0
BSA 2 1.56 128.5 ± 14.4
C3bi-RBC None 2 (+)a 10.5 ± 2.2
AGE-BSA 2 (+) 17.5 ± 4.8
Zymosan None 2 (+)' 242.6 t 19.5
AGE-BSA 2 (+) 231 .0 ± 22.4MOSSER ET AL.
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uptake to approximately the same extent but exerted a maximal effect with
different amounts of material, ranging from 80 to 300 wg/ml. This presumably
reflects the presence of differing amounts of particular AGES in the AGE-BSA
preparation. The inhibition of parasite binding was most dramatic when macro-
phages were first pretreated with AGE-BSA and the parasites were added in the
continuous presence of the inhibitor. The data presented in Table I and Fig. 1
were obtained under this condition. Macrophage pretreatment for 20 min, with
subsequent inhibitor, washout before the addition of parasites also resulted in
inhibition of parasite binding. Pretreated monolayers bound from 64 to 72% of
the amount oforganisms bound to parallel untreated monolayers (two independ-
ent experiments done in triplicate). This is an inhibition of 28-36%, which is
approximately half the inhibition (60%) seen when parasites are added to mon-
olayers in the continuous presence of AGE-BSA . Fig. 1 shows a concentration-
dependent inhibition by AGE-BSA ranging from 25 to 300 ug/ml . Incubation
of monolayers with AGE-BSA at 300 Wg/ml caused no evidence of cell toxicity.
Monolayers retained the same number of cells (in the range of 1 .0-1 .2 X 105
cells/coverslip) with unchanged morphology. The protein content of untreated
monolayers (20.6 ug) was comparable to BSA-treated monolayers (23.2 Fcg) and
those treated with AGE-BSA (21 .4 Ag). Further, the inhibition of macrophage
uptake of leishmania promastigotes by AGE-BSA was specific. The binding and
uptake of either C3bi-coated red blood cells or zymosan by macrophages was
not affected by preincubation with AGE-BSA (Fig. 1). After a 45-min incubation,
87% of the macrophages in a monolayer were positive for zymosan uptake,
scored positive when a cell had internalized three or more particles, and 74% of
the cells had formed rosettes with C3bi-red blood cells. Preincubation ofparallel
monolayers with AGE-BSA did not affect their recognition, with 83% of the
cells in the monolayer continuing to efficiently take up zymosan, and 78% of the
cells rosetting C3bi-red blood cells. The monoclonal antibody to the macrophage
CR3, anti-Mac-1, inhibits the rosetting of the same preparation of C3bi-RBC by
75%, while AGE-BSA does not. In addition to demonstrating the specificity of
AGE-BSA inhibition, these data emphasize the distinction between the C3bi
receptor and the AGE-protein receptor. The inhibition of parasite binding by
AGE-BSA works at the level of the macrophage, as promastigotes that were
preincubated with AGE-BSA (100 kg/ml) for 30 min and then washed before
incubation with macrophages bound to the same extent as control parasites.
Preincubation of macrophages with BSA linked to the specific AGE product,
FFI, did not reduce uptake (Table I). This latter result is surprising, since FFI-
BSA has been observed (4) to inhibit the binding and uptake of AGE-BSA by
macrophages. Since the AGE products are a complex family of molecules, this
result may reflect increased binding of a subset of AGE-products that are able
to compete with leishmania, or it may reflect a subset of receptors for which
AGE and leishmania can compete but FFI can not.
Preincubation of macrophages with AGE-BSA and anti-Mac-1, a monoclonal
antibody to the CR3, inhibits the uptake of promastigotes by macrophages by
88% (Table I). The combined effect of these two agents is specific, as the uptake
of latex beads or IgG-coated red blood cells proceeds uninhibited in their
presence (data not shown).144
￿
MACROPHAGE RECEPTOR FOR LEISHMANIA PROMASTIGOTES
Previous workers (13, 14) have demonstrated a macrophage respiratory burst
triggered by the uptake of leishmania promastigotes. Addition of either AGE-
BSA or anti-Mac-1 to the monolayer reduced the amount of parasite binding by
-50%, with a concomitant reduction in the macrophage respiratory burst. In
combination, these two agents reduced the burst by 80% (Table 1). Incubation
of the monolayers with either unconjugated BSA or FFI-BSA did not affect the
respiratory burst, arguing against a nonspecific quench. Further, the burst
triggered by zymosan (242.6 nmol of 02 per milligram protein) is not affected
by the presence of 125 'cg/ml AGE-BSA (231 .0 nmol of 02 per milligram
protein). The presence of superoxide dismutase (150 U) decreases by -90% the
respiratory burst triggered by leishmania (n = 3), equivalent to an average of
10.2 nmol 02 per milligram protein . Parasites alone cause only a very slight
reduction of cytochrome C, (equivalent to 14.2 ± 2.7 nmol 02 per milligram
protein ; n = 5), as did parasites added to glutaraldehyde-treated macrophages.
Neither exceeded 15% ofsimultaneous values for stimulated cells. Thus, parasites
entering via either the AGE receptor or the receptor for C3bi can trigger the
respiratory burst.
Further work is needed to ascertain the role of both these uptake systems in
different phagocytes and on the fate of various leishmania organisms. These
future studies may provide insight into specific cellular tropisms characteristic of
a given species, and to the pathological sequelae associated with leishmania
infection.
Summary
In this paper we demonstrate the involvement ofthe macrophage receptor for
advanced glycosylation endproducts (AGE) in the phagocytosis of Leishmania
major promastigotes. Blocking of this receptor with the ligand, AGE-BSA, leads
to a 50% decrease in phagocytosis relative to controls, and a comparable decrease
in the respiratory burst. The inhibitionofphagocytosis by AGE-BSA was specific
to leishmania. The binding of zymosan or C3bi-RBC and the phagocytosis of
IgG-RBC or latex beads was not affected by the presence of AGE-BSA. Blocking
of both the AGE receptor and CR3 decreases leishmania binding by nearly 90%,
and reduces the respiratory burst by 80%, indicating that the two receptors
account for the bulk of L. tropica promastigote recognition and uptake by the
macrophage.
Receivedfor publication 18June 1986 and in revisedform 16 September 1986.
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